Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark. The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, the process of myelin degradation that underlies MS. Preliminary imaging data have shown encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, which are often difficult to detect with conventional imaging.
This imaging approach could significantly enhance the development of MS therapies, including Quantum’s own investigational candidate Lucid-MS. For Lucid-MS, an Investigational New Drug (IND) submission for a Phase 2 trial was submitted to the FDA in March 2026. The ability to directly visualize demyelination in vivo would provide a powerful tool for assessing treatment efficacy in clinical trials and potentially accelerate drug development.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is developing Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation. The company also retains a 19.84% ownership stake in Unbuzzd Wellness Inc., which markets UNBUZZD, an over-the-counter product for alcohol misuse, and is entitled to royalty payments on sales.
The full press release is available at https://ibn.fm/4IZ0y. For more information on Quantum BioPharma, visit the company’s newsroom at https://ibn.fm/QNTM.
